Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

24 Feb 2023

Abstract excerpt

Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein Tyrosine Phosphatases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36911405
DOI: 10.3389/fgene.2023.1110656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in CancerPMID 36911405Read ↗

Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy TargetSemantic proximity Read ↗

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionSemantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

CIP2A Inhibits PP2A in Human MalignanciesSemantic proximity Read ↗

High expression of HSP90 is associated with poor prognosis in patients with colorectal cancerSemantic proximity Read ↗

Prognostic, mutational, and immunologic analysis of CD90 in pan-cancer and validation of DHDK as a drug candidate.Semantic proximity Read ↗

Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer ProgressionSemantic proximity Read ↗

90K (Mac-2 BP) and galectins in tumor progression and metastasisSemantic proximity Read ↗

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.Semantic proximity Read ↗

Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations.Semantic proximity Read ↗

Extracellular HSP90α-LRP1 Signaling Promote Pancreatic Cancer Metastasis and Chemoresistance Via Regulating Epithelial-To-Mesenchymal TransitionSemantic proximity Read ↗

ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.